SEC Filings Reveal GlaxoSmithKline's 13% Stake in This Massachusetts Biotech Post author:Sam Post published:November 16, 2017 Post category:BioPharma A filing with the SEC indicates that Glaxo now has a 13 percent stake in Spero Therapeutics. Source: BioSpace You Might Also Like AmerisourceBergen Pays $815M Cash for Drug Wholesaler H. D. Smith November 20, 2017 Alere Achieves FDA Clearance for Alere Reader Platform and Alere BinaxNOW Influenza A & B Card 2 April 10, 2017 3 Biotech Stocks That Exploded in 2017 December 4, 2017
Alere Achieves FDA Clearance for Alere Reader Platform and Alere BinaxNOW Influenza A & B Card 2 April 10, 2017